HIPAA Compliance for Osteoporosis APCM Checklist

Ensure AI voice systems use multi-factor verification before discussing bone density results or denosumab schedules.

All automated reminders for bisphosphonate therapy or calcium supplements must be transmitted via encrypted channels.

Review logs of AI-patient interactions regarding fall risk assessments to ensure no unauthorized data exposure.

Confirm a signed Business Associate Agreement is in place for any AI platform handling osteoporosis patient data.

Secure documented consent from Medicare patients before enrolling them in AI-driven osteoporosis monitoring programs.

Use encrypted portals when sending bone density scan orders to imaging centers to prevent PHI leaks.

Ensure vitamin D and calcium lab results are communicated through secure, authenticated patient portals or encrypted AI calls.

Restrict access to DEXA T-scores and Z-scores to authorized clinical staff involved in the APCM care plan.

If using patient data for secondary fracture prevention research, ensure all PHI is removed per HIPAA Safe Harbor rules.

Ensure that fall risk assessment data collected via mobile or phone is stored in a HIPAA-compliant database.

Record every AI-driven touchpoint for denosumab monitoring within the EHR to meet APCM audit requirements.

Maintain secondary fracture prevention plans in encrypted digital environments to protect sensitive medical history.

Provide specific training on handling osteoporosis-specific PHI, such as bone scan reports and medication adherence logs.

Ensure osteoporosis care plans and medication schedules are backed up in a secure, off-site HIPAA-compliant location.

Implement digital signatures for logs tracking bisphosphonate administration to prevent unauthorized data alteration.